This paper introduces CRISPR-StAR, an in vivo CRISPR screening platform with improved normalization and analysis tools, showing it can identify tumor suppressor gene effects not observable in vitro.

Cell Reports Methods · Jun 1, 2026Peer-reviewedGenomics

Identification of a lineage-agnostic splicing signature caused by PRMT5 inhibition

Matthew R. Tonini, Samuel R. Meier, Shangtao Liu, Kevin M. Cottrell, John P. Maxwell, Jannik N. Andersen, Alan Huang, Luisa Cimmino, Kimberly J. Briggs

This paper identifies a splicing signature caused by PRMT5 inhibition in MTAP-deleted cancers, showing histology-agnostic splicing changes and potential as a biomarker for PRMT5 inhibitor activity.

bioRxiv · Mar 30, 2026 · PreprintCancer Biology

Tumor suppressor collateral damage screens reveal mRNA homeostasis protein HBS1L as a novel vulnerability in ch9p21 driven FOCAD deleted cancer

Hongxiang Zhang, Matthew R. Tonini, Lauren Catherine M. Martires, Helena N. Jenkins, Charlotte B. Pratt, Eden N. Gordon, Shan-Chuan Zhao, Ashley H. Choi, Samuel R. Meier, Tenzing Khendu, Shangtao Liu, Binzhang Shen, Hannah Stowe, Katerina Pashiardis, Xuewen Pan, , Teng Teng

The paper identifies HBS1L as a synthetic lethal target in FOCAD-deleted cancer through combinatorial CRISPR screens and validates its dependency via genetic manipulation and in vivo experiments.

Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · Oct 15, 2025Peer-reviewedCancer Biology